Despite COVID-19 Vaccine Trial Delay, AstraZeneca Is Still a Buy, Says Analyst, , on September 25, 2020 at 9:23 pm

By
On September 25, 2020
Tags:

Does AstraZeneca (AZN) still have a fighting chance in the COVID-19 vaccine race? Earlier this month, the healthcare giant paused the Phase 3 study of AZD1222, its experimental COVID-19 vaccine developed as part of a collaboration with the University of Oxford, after one of the participants developed an unexplained illness, a potential adverse effect. This effect was later described as transverse myelitis, a demyelinating condition.Even though the UK study has resumed, the U.S. study remains on hold. Against this backdrop, AZN released the protocol for the trial, demonstrating the “rigorous” criteria of the interim analysis, in SVB Leerink analyst Andrew Berens’ opinion.AZD1222’s criteria for success is based on the FDA’s Guidance for Industry regarding COVID-19 vaccine development, which asserts that an observed vaccine efficacy (VE) point estimate should be at least 50%, and that the lower bound of the confidence interval (CI) should be over 30%.AZN’s first interim analysis (IA) will occur after 75 COVID-19 cases are reported, with statistical significance being achieved if the two-sided 99.69% confidence interval (CI) at the time is over 30%.Looking at its peers, Moderna’s first interim analysis will occur after 53 COVID-19 cases are reported and will have a 74.1% efficacy boundary criteria to be considered a success. For the Pfizer/BioNTech SARS-COV-2 vaccine study, the first interim analysis will take place after 32 events, with an efficacy threshold of 76.9% efficacy.On top of this, Berens points out that the protocol was amended to include an exclusion criterion of a history of demyelinating conditions. He added, “In addition, the incidence of adverse events of special interests, which includes demyelinating conditions, is part of the safety/tolerability primary endpoint, which further reflects the steps taken by the company following the two cases of this adverse event. Importantly, the Pfizer/BioNTech and Moderna’s vaccine protocols do not mention demyelinating conditions in their protocols, suggesting the finding may be circumscribed to the AZN program.”Given all of the above, Berens commented, “Because of the trial hold and the relatively high number of COVID-19 cases needed for an interim analysis versus other protocols, we believe AZN has lost the lead and may not be the first vaccine to reach a potential emergency use authorization (EUA). Based on the protocol designs, we think that Pfizer/BioNTech BNT162b2 will take the lead and, depending on when the AZN trial restarts, Moderna’s mRNA-1273 may follow.”That being said, Berens still believes AZN has strong long-term growth prospects. With this in mind, he rates the stock an Outperform (i.e. Buy) along with a $65 price target. Should the 5-star analyst’s thesis play out, a twelve-month gain of 17% could potentially be in the cards. (To watch Berens’ track record, click here)All in all, other analysts echo Berens’ sentiment. 4 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Given the average price target of $77.38, the upside potential comes in at 39%. (See AstraZeneca stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.,

Despite COVID-19 Vaccine Trial Delay, AstraZeneca Is Still a Buy, Says AnalystDoes AstraZeneca (AZN) still have a fighting chance in the COVID-19 vaccine race? Earlier this month, the healthcare giant paused the Phase 3 study of AZD1222, its experimental COVID-19 vaccine developed as part of a collaboration with the University of Oxford, after one of the participants developed an unexplained illness, a potential adverse effect. This effect was later described as transverse myelitis, a demyelinating condition.Even though the UK study has resumed, the U.S. study remains on hold. Against this backdrop, AZN released the protocol for the trial, demonstrating the “rigorous” criteria of the interim analysis, in SVB Leerink analyst Andrew Berens’ opinion.AZD1222’s criteria for success is based on the FDA’s Guidance for Industry regarding COVID-19 vaccine development, which asserts that an observed vaccine efficacy (VE) point estimate should be at least 50%, and that the lower bound of the confidence interval (CI) should be over 30%.AZN’s first interim analysis (IA) will occur after 75 COVID-19 cases are reported, with statistical significance being achieved if the two-sided 99.69% confidence interval (CI) at the time is over 30%.Looking at its peers, Moderna’s first interim analysis will occur after 53 COVID-19 cases are reported and will have a 74.1% efficacy boundary criteria to be considered a success. For the Pfizer/BioNTech SARS-COV-2 vaccine study, the first interim analysis will take place after 32 events, with an efficacy threshold of 76.9% efficacy.On top of this, Berens points out that the protocol was amended to include an exclusion criterion of a history of demyelinating conditions. He added, “In addition, the incidence of adverse events of special interests, which includes demyelinating conditions, is part of the safety/tolerability primary endpoint, which further reflects the steps taken by the company following the two cases of this adverse event. Importantly, the Pfizer/BioNTech and Moderna’s vaccine protocols do not mention demyelinating conditions in their protocols, suggesting the finding may be circumscribed to the AZN program.”Given all of the above, Berens commented, “Because of the trial hold and the relatively high number of COVID-19 cases needed for an interim analysis versus other protocols, we believe AZN has lost the lead and may not be the first vaccine to reach a potential emergency use authorization (EUA). Based on the protocol designs, we think that Pfizer/BioNTech BNT162b2 will take the lead and, depending on when the AZN trial restarts, Moderna’s mRNA-1273 may follow.”That being said, Berens still believes AZN has strong long-term growth prospects. With this in mind, he rates the stock an Outperform (i.e. Buy) along with a $65 price target. Should the 5-star analyst’s thesis play out, a twelve-month gain of 17% could potentially be in the cards. (To watch Berens’ track record, click here)All in all, other analysts echo Berens’ sentiment. 4 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Given the average price target of $77.38, the upside potential comes in at 39%. (See AstraZeneca stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

168 Robinson Road
#12-01 Capital Tower
Singapore 068912

New York

Coming Soon!

Dubai

Coming Soon!

Market Coverage